All Industries

USDT on TRON Surpasses $80 Billion, Strengthening TRON’s Position as the Leading Stablecoin Network

TRON DAO

June 26, 2025 - Geneva, Switzerland - TRON DAO announced today that the total circulating supply of USDT on the TRON blockchain has exceeded $80 billion, further cementing TRON’s position as the top blockchain for USDT activity. With USDT holding more than 63 percent of the global stablecoin market and surpassing 155 billion dollars in circulation, over half of that supply is issued on TRON. Since January 2025, the supply of USDT issued on the TRON network has grown by approximately 20 billion, according to a data platform Token Terminal. TRON continues to lead all blockchain networks in USDT issuance, transaction volume, and daily user activity. TRON has established itself as the preferred settlement network for stablecoins, hosting around 60 percent of payment transaction volume. Its scale and efficiency continue to position it as the backbone for digital dollar movement across borders and diverse financial applications. As of June 2025, TRON processes over 8.9 million daily transactions and has surpassed 315 million total user accounts. Additionally, the network facilitates an average of $21.5 billion in daily USDT transfers. With over 1 million unique wallets transacting USDT each day, TRON also leads in active stablecoin wallet usage, representing 28 percent of global active addresses. With stablecoins playing an increasingly important role in cross-border settlement, financial access, and dollarization in emerging markets, TRON has established itself as one of the most widely used blockchain networks in the world. Its combination of scale, speed, and low transaction costs has made it the preferred environment for stablecoin activity worldwide. “TRON’s success is grounded in its alignment with the core values of crypto—openness, user empowerment, and real-world utility,” said Justin Sun, founder of TRON. “USDT on TRON has become the go-to choice for millions of people because it works—it’s fast, efficient, and easy to use. The TRON ecosystem remains focused on building reliable infrastructure for the next generation of digital finance.” TRON’s leadership in the stablecoin space continues to evolve to meet growing institutional demand. In April 2025, World Liberty Financial chose TRON to launch its USD1 stablecoin, which began minting earlier this month. Additionally, the TRON ecosystem has deepened its focus on financial compliance through the T3 Financial Crime Unit (T3 FCU), a joint initiative with Tether and TRM Labs. Since launch, T3 FCU has worked with law enforcement agencies worldwide to freeze over $160 million linked to illicit activity. As the digital dollar economy continues to expand, TRON remains a core pillar of the infrastructure driving greater efficiency and financial inclusion. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON blockchain has experienced significant growth since its MainNet launch in May 2018. TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin, exceeding $80 billion. As of June 2025, the TRON blockchain has recorded over 315 million in total user accounts, more than 10 billion in total transactions, and over $21 billion in total value locked (TVL), based on TRONSCAN. TRONNetwork | TRONDAO | X | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Yeweon Park press@tron.network Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

June 26, 2025 12:46 PM Eastern Daylight Time

Image

IotaComm® Sponsors Healthy Green Schools & Colleges Program to Advance Healthier, Smarter School Environments Nationwide

IotaComm

IotaComm, Inc. ("IotaComm"), a next-generation wireless communications and Internet of Things (IoT) solution provider, is proud to announce its official sponsorship of the Healthy Green Schools & Colleges (HGSC) program. As a sponsor, IotaComm is supporting the nationwide effort to transform K–12 and higher education facilities into cleaner, safer, and more sustainable environments for students and staff—no matter the zip code. HGSC, a program of the Healthy Schools Campaign, is designed to help school facility professionals identify low- and no-cost strategies to improve indoor air quality (IAQ), sustainability, and operational efficiency. Developed in collaboration with school facilities experts, the program equips institutions with the tools to address workforce development, resource constraints, and long-standing environmental health disparities, especially in historically underfunded communities. “This partnership isn’t just about measuring air quality—it’s about making it meaningful,” said Charlie Thiel, Chief Revenue Officer at IotaComm. “Where others offer a snapshot, we provide the full movie. Our Delphi360™ platform collects and transforms data into operational intelligence that district leaders can use to help their schools not just meet standards, but strategically improve environments where students learn and teachers work.” IotaComm’s Delphi360™ platform uses secure connectivity and battery-powered LoRaWAN® sensors to collect key IAQ parameters—including carbon dioxide (CO₂), particulate matter (PM2.5, PM10), temperature, humidity, and VOCs—every 30 minutes. This data is then transformed into actionable insights that empower district leaders, superintendents, and facility teams to make smarter, evidence-based decisions. These insights are especially valuable in helping schools meet HGSC certification requirements, such as CO₂ monitoring across 100% of occupied spaces. “The highest value of IAQ data is in trend analysis—not just static readings,” Thiel added. “Delphi360 helps districts identify issues before they escalate and demonstrates measurable improvements that strengthen transparency with their communities.” A Data-Driven Path to Healthier Schools HGSC’s three-step improvement model—Assess, Commit, Improve—guides institutions at every stage of their sustainability journey: Assess: Schools complete a free online self-assessment to evaluate their current performance and score themselves against the HGSC standard. Commit: Schools officially join the program and gain access to training, peer support, and best-practice guidebooks. Improve: Schools implement changes at their own pace, with expert guidance to address root causes, track progress, and eventually achieve certification status. “Unhealthy indoor air, poor ventilation, and harmful chemicals from outdated maintenance practices put students and educators at risk and impact learning outcomes,” said Sara Porter, Program Director of Healthy Green Schools & Colleges and Vice President of External Affairs at Healthy Schools Campaign. “These challenges are most acute in schools serving low-income communities and students of color. HGSC is designed to remove systemic barriers and create healthier learning environments for all.” “IotaComm’s data-driven approach enhances our program by turning indoor air quality goals into everyday operational improvements,” Porter added. “It’s this kind of practical innovation that helps schools move from intention to impact.” Supporting a Mission of Equity, Transparency, and Impact For IotaComm, this sponsorship represents a natural extension of its mission to deliver scalable, sustainable technology that bridges the gap between data, equity, and action in public infrastructure. We are not just supporting an initiative – we’re helping redefine what it means to create safe, equitable learning environments in the 21 st century. The partnership also aligns with IotaComm’s active crowdfunding campaign, which invites everyday investors to fuel the company’s growth and mission of making smart, healthy infrastructure accessible to every community. To learn more about the Healthy Green Schools & Colleges program and IotaComm’s role as a sponsor, visit: www.healthygreenschools.org/sponsors/iotacomm About IotaComm, Inc. IotaComm is a wireless communications and data services company that provides secure, carrier grade low-power connectivity for the Internet of Things (IoT). Through its nationwide FCC licensed 800 MHz spectrum portfolio and proprietary Delphi360™ platform, IotaComm delivers critical data-driven solutions for smart buildings, smart cities, and sustainable infrastructure. IotaComm leverages the globally adopted LoRaWAN® standard and is a member of the LoRa Alliance®, the leading global association driving the adoption of LoRaWAN® worldwide. Headquartered in Chapel Hill, NC, with operations in Allentown, PA, IotaComm is committed to innovation, sustainability, and delivering value for customers, communities, and shareholders. For more information, visit www.iotacomm.com. About Healthy Schools Campaign Healthy Schools Campaign (HSC) works to ensure all students have access to environments that support health and academic success. HSC provides stakeholders with tools and leadership skills to influence health and wellness policy, advocates for practical reforms, and builds strong coalitions to support sustainable school health initiatives. Learn more at www.healthyschoolscampaign.org. Contact Details Kim Velez, Chief of Staff to the CEO +1 484-861-2994 kvelez@iotacomm.com Company Website https://iotacomm.com/

June 26, 2025 09:45 AM Pacific Daylight Time

News Release

Rankulate Launches to Help Businesses Scale SEO With Lean ROI-Focused Strategies

Rev Up Marketers

Rankulate, a newly launched SEO consultancy, officially opens its doors to help businesses scale organic growth through lean, results-driven strategies. Founded by SEO expert Adrian Podyma, Rankulate offers consultant-led support tailored for startups, scale-ups, and enterprise teams seeking clarity, speed, and measurable performance without the overhead of a traditional agency. What sets Rankulate apart is its commitment to hands-on leadership and high-impact execution. Every strategy is directly overseen by Podyma, ensuring senior-level insight, tight alignment with business goals, and faster implementation. The consultancy adapts to the scale of each project, assembling the right specialists as needed—without losing strategic focus or adding layers of complexity. With over a decade of experience leading SEO programs across diverse industries—and managing teams of up to 20 SEO professionals per project—Podyma brings both strategic clarity and operational depth to each engagement. Rankulate is positioned to support businesses navigating complex SEO challenges with a streamlined, performance-first approach. “SEO should be a growth engine, not a bottleneck,” says founder Adrian Podyma. “Rankulate was built to deliver lean, accountable, ROI-focused SEO—led by someone who’s been in the trenches.” Rankulate is now accepting clients across B2B, SaaS, and e-commerce sectors. To learn more, visit [ www.rankulate.com ]. About Rankulate Rankulate is a boutique SEO consultancy based in Katowice, Poland, founded by Adrian Podyma. Focused on lean, ROI-driven strategies, the firm helps businesses solve complex SEO challenges through personalised, consultant-led support. With deep expertise across technical SEO, content strategy, and scalable execution, Rankulate delivers clarity, speed, and measurable growth—without the unnecessary layers of traditional agencies. Learn more at [ www.rankulate.com ]. Contact Details Rankulate Adrian Podyma contact@rankulate.com Company Website https://rankulate.com/

June 26, 2025 11:19 AM Eastern Daylight Time

Bonsai Launches Telemetry Platform to Connect All Farm Equipment — Autonomous or Not

Bonsai Robotics

Bonsai Robotics Inc. ("Bonsai"), a leading developer of agriculture AI solutions, announced the launch of its proprietary offering for building a transformative connected farming platform for high-value crops. The company’s software ecosystem, Teletrace ™, will expand from support of its fully autonomous machines to enabling conventional tractors and implements to be monitored and managed through the same digital interface. This new intelligent management solution is powered by the Topcon CL-55, a compact telemetry device that plugs directly into the existing CAN bus — a standard interface on most modern tractors and implements. With this connection, real-time machine data is transmitted via Topcon’s CloudLink service and seamlessly integrated into Bonsai’s cloud platform. Growers can monitor and manage every piece of equipment — new or old, autonomous or not — through a single, unified interface powered by Bonsai’s Teletrace ecosystem. “Bonsai’s mission is to bring the AI revolution to the field by unlocking the ability to reimagine how machines are built, deployed, and managed,” said Tyler Niday, CEO and co-founder of Bonsai. “Our solution is no longer limited to just autonomous equipment. Now, any farm machinery, regardless of make or vintage, can be transformed into a smart machine utilizing Teletrace allowing growers to manage mixed fleets from anywhere and track operational utilization, performance and metrics such as harvest rate, input usage and more.” Bonsai’s autonomy system is purpose-built for the harsh, variable conditions of orchard environments – where GPS, LiDAR, and satellite-based systems often fall short, and dust is a constant challenge. In addition, the company’s vision-based autonomy stack enables reliable operation under dense canopy, uneven terrain and without GPS dependency. With Teletrace, growers can now reduce operator error through digital job dispatching and smart implement control and prepare for phased autonomy adoption without the cost of full equipment upgrades. “Permanent crops have seen mechanical innovation, but not digital transformation,” Niday added. “We are here to change that. With Bonsai, the orchard is no longer an offline black hole of information, but now a connected, intelligent system.” This launch follows successful deployments across almonds, pistachios and citrus operations in California and Australia, where growers are using Bonsai to automate spraying, mowing, disking, shaking and sweeping— and now, to track and manage conventional equipment as well. The company’s long-term vision is to manage a diverse set of machines across brands, horsepower ranges, and autonomy levels from a single, intuitive platform. About Bonsai Robotics Bonsai Robotics Inc. is reimagining farming production systems with an AI-first approach to provide vision-based autonomous solutions for harsh environments. Based on patented AI models, a leading orchard data set and computer-vision software, Bonsai’s solutions integrate seamlessly to make OEM equipment operate autonomously. Bonsai technology can navigate in GNSS-denied environments, without a cellular or internet connection, making the highly affordable technology ideal for the toughest physical conditions where dust, darkness, debris, elevation changes and vibration may occur. Learn more at https://www.bonsairobotics.ai/ Contact Details Bonsai Media Contact: Erika Poppelreiter erika@soldiercreekcommunications.com

June 26, 2025 08:15 AM Pacific Daylight Time

Image

News Release

Tonic Blooms Introduces Flower Delivery with Fresh Designs Same-Day Service

Rev Up Marketers

Tonic Blooms is rewriting the playbook for flower delivery in Toronto. Co-founded by Raphi Aronowicz and Michael Smaye, Tonic Blooms was created out of personal frustration with unreliable and underwhelming flower delivery experiences. Today, the company has become a trusted solution for customers looking to send beautiful, hand-tied bouquets with ease, speed, and confidence. "We knew there had to be a better way to send flowers," says Raphi Aronowicz, co-founder of Tonic Blooms. "After too many disappointing deliveries, especially around big moments like Valentine's Day, we set out to create a service that delivers fresh, stunning arrangements exactly when people need them." Tonic Blooms offers on-demand delivery in Toronto and same-day delivery across Southern Ontario, with plans to expand nationwide. Their curated collection of bouquets and indoor plants strikes a balance between simplicity and variety, eliminating the overwhelming product catalogs typical of many online florists. From elegant tulip bunches to their signature garden-style Farmboy bouquet, every arrangement is fresh, thoughtfully designed, and sourced directly from partnering growers. "Our goal is simple: make someone's day, and make it easy," adds Michael. "From placing the order to delivery, we handle every detail to ensure a stress-free experience." What sets Tonic Blooms apart is its commitment to customer happiness. The company backs every order, staying in touch with both sender and recipient throughout the delivery process to ensure everything arrives on time and looks perfect. With a focus on quality, transparency, and service, Tonic Blooms has quickly earned a loyal customer base throughout Southern Ontario, becoming the go-to option for birthdays, anniversaries, apologies, and spontaneous surprises. For media inquiries, interviews, or partnership opportunities: Contact: Raphi Aronowicz Email: support@tonicblooms.com Website: https://tonicblooms.com Contact Details Tonic Blooms Raphi Aronowicz support@tonicblooms.com Company Website https://tonicblooms.com

June 26, 2025 11:14 AM Eastern Daylight Time

Back to the Doctor’s Office: As Telehealth Declines, Demand for In-Person Care Drives a Medical Real Estate Shift

The Hoyt Organization

In the wake of the COVID-19 pandemic, virtual healthcare saw a historic surge. But now, a new trend is emerging: patients are returning to their doctors' offices — and they’re doing it in droves. According to new data from the Center for Telehealth and e-Health Law (CTeL), telehealth use has entered a steady decline since its peak during the pandemic. With the expiration of emergency policies that once expanded access to virtual care, analysts project a staggering 12 million telehealth appointments will be lost annually. This shift is placing renewed importance on brick-and-mortar medical practices—and driving an urgent need for physical medical office space in urban hubs across the country. “This isn’t just a statistical dip — it’s a fundamental shift,” says Kurt Hackett, Vice President of Asset Management at Rethink Capital, which owns and manages the Medical Pavilion at 939 Ellis Street in San Francisco. “We're seeing patients of all types of medical disciplines re-emphasize the value of in-person care, and providers are responding by ramping up their physical presence.” A Premier Option in San Francisco's Healthcare Corridor At the heart of the resurgence of in-person care is the Medical Pavilion at 939 Ellis Street, a premier medical office building situated in San Francisco’s vibrant healthcare corridor along Van Ness Avenue. Nestled close by Sutter Health’s CPMC Van Ness Campus, the Pavilion offers a strategic, central location for healthcare providers looking to expand or relocate to a high-demand urban market. “939 Ellis Street is perfectly positioned for providers who need immediate access to hospital systems, public transit, and city and suburban population,” says Hackett. “It checks all the boxes for modern medical delivery.” The property features: Proximity to top-tier health systems and medical campuses Full and partial floor suites to accommodate a wide range of medical uses Infrastructure designed to meet today’s clinical and compliance needs On-site parking, and mass transit accessibility What’s Driving the In-Person Comeback? Several factors are contributing to the retreat from telehealth and the renewed interest in physical appointments: Clinical Limitations of Virtual Care: While video consultations offer convenience, many conditions — such as orthopedic and cardiac issues, cancer care, and urological disorders — require physical examinations, lab work, and imaging that simply cannot be done remotely. Insurance Reimbursement Reversions: As emergency-era policies sunset, insurers are reverting to pre-COVID reimbursement models which often favor in-person visits. This reimbursement structure creates an incentive for providers to bring patients back into the office. Digital Fatigue: After years of Zoom meetings, online learning, and virtual appointments, both patients and providers are reporting burnout with screen-based interactions. Trust and Patient Experience: Research continues to show that face-to-face care fosters stronger patient-provider relationships and improves long-term treatment outcomes—something digital platforms have struggled to replicate. Investment Strategies Follow the Trend For real estate investors and healthcare providers alike, the shift back to in-person care is shaping portfolio decisions in key metro markets like San Francisco, where aging medical stock and strong population density make modern medical offices particularly attractive. “Providers are increasingly seeking newer, well-located facilities that reflect the current standards of care,” Hackett explains. “Our goal at the Medical Pavilion is to offer not just square footage, but an ecosystem where quality care can thrive.” A New Era of Care Delivery As the pendulum swings away from virtual-first healthcare, the demand for high-quality, strategically located medical office space is expected to grow — particularly in regions like the Bay Area, where healthcare innovation and patient demand continue to intersect. For providers seeking to adapt and grow in this changing environment, properties like the Medical Pavilion at 939 Ellis Street represent a unique opportunity: the chance to be part of San Francisco’s healthcare future, right in the heart of its medical corridor. For leasing inquiries at 939 Ellis St., contact Trask Leonard, president and CEO of Bayside Realty Partners at tleonard@baysiderp.com. About Medical Pavilion at 939 Ellis Street: Positioned in the Van Ness medical hub, Medical Pavilion at 939 Ellis Street is a purpose-built medical office building offering flexible, large-scale space options for healthcare users, with direct access to public transit, nearby hospitals, and the city’s primary healthcare corridor. It can accommodate a range of specialties. It boasts a scenic rooftop terrace and available parking. Contact Details Leeza Hoyt +1 310-343-3197 llhoyt@hoytorg.com Company Website https://939-ellis.com/

June 26, 2025 08:00 AM Pacific Daylight Time

NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads

The Finance Herald

NeuroSense Therapeutics (NASDAQ: NRSN)* has completed a key pre-submission meeting with Health Canada for its ALS drug PrimeC, signaling potential upcoming eligibility for Canada’s fast-track approval pathway (NOC/c). The positive tone reported from the meeting could signal accelerated Canadian approval coming soon and could also potentially advance negotiations for the partnership with a global pharma player. With strong Phase 2b data and a potential $100–150M of peak revenue from Canadian market alone, this milestone could be a catalyst for regulatory momentum and investor revaluation. ‎ NeuroSense Therapeutics (NASDAQ: NRSN) may be nearing a turning point in its ALS drug development journey, and the market is starting to take notice. The Israeli biotech just disclosed that it held a pivotal pre-submission meeting with Health Canada for PrimeC, its lead ALS candidate, potentially setting the stage for both early approval and the finalization of a major pharma partnership. In a Form 6-K filed with the SEC, NeuroSense confirmed the completion of a pre-New Drug Submission (pre-NDS) meeting with regulators to explore eligibility for Canada’s fast-track approval mechanism, known as the Notice of Compliance with Conditions (NOC/c). The company described the discussion as “constructive” and left the meeting “highly encouraged”, language that signals regulatory alignment and opens the door for PrimeC to potentially Canadian patients much sooner than expected. For ALS patients in Canada—and a company with a current ~$52 million valuationm that kind of timeline could prove transformational. But the Health Canada development is more than just a regulatory checkpoint—it’s a potential trigger for something bigger. Back in December 2024, NeuroSense signed a binding term sheet with a global pharmaceutical company, covering full Phase 3 funding, upfront cash, milestone payments, and double-digit royalties. A positive signal from Canadian authorities could be the validation needed to cement that deal and set the stage for global expansion. PrimeC already has data to back up its ambitions. In its Phase 2b PARADIGM trial, the therapy showed a 36% slowdown in ALS progression and a 43% improvement in survival compelling outcomes in a field where treatment options are few and efficacy gains are hard-won. That performance is part of what’s drawing interest from the industry—and why a Canadian approval could serve as a powerful launchpad, both commercially and strategically. The Canadian ALS market alone could support $100–150 million in annual peak sales, according to company estimates. But what’s arguably more valuable is the opportunity to generate real-world data and establish market traction ahead of broader approvals, particularly in the U.S. and Europe. Investors likely won’t have to wait long for clarity. NeuroSense expects to receive official meeting minutes from Health Canada shortly and will update the market once eligibility is confirmed. If successful, the NDS filing and Phase 3 launch would likely follow. In a sector defined by long timelines and uncertain outcomes, NeuroSense now finds itself in a rare position, with validated clinical data, regulatory momentum, and a pending global partnership that could reprice the story entirely. The next few months may determine whether PrimeC becomes not only a commercial product, but also a cornerstone of a much larger biotech success. ‎ Read more from the Finance Herald The New Digital Iron Curtain: How the EU’s Digital Services Act Threatens American Free Speech The Nobel Dilemma: Should Trump Embrace or Reject a Controversial Legacy? New York City’s Political Revolution: Zohran Mamdani’s Far-Left Vision Sparks National Debate States Challenge Trump Administration’s Funding Cuts in Major Legal Battle Heating Up: Power Crisis Strikes the Eastern U.S. Amid Record Temperatures ‎ ‎ * ⚠︎ Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from NeuroSense Therapeutics Ltd. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. We are not responsible for any price targets that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details ‎ media.globalmarkets@gmail.com

June 26, 2025 09:24 AM Eastern Daylight Time

Image

EDGE Boost Named Preferred Payment Method for World Series of Poker Event Series

EDGE Boost

EDGE Boost by EDGE Markets, a financial platform for smart bettors and gamblers, has partnered with World Series of Poker, the premier series of worldwide poker tournaments. The EDGE Boost debit card is now the preferred payment method for WSOP, offering ease of payment, safety and several exclusive on-site perks for tournament players. In past tournaments, WSOP players were limited to $10,000 per transaction and had to complete a lengthy approval process, often resulting in frequent cash deposits. Now, those using the EDGE Boost card through PayPal checkout can bypass traditional credit card verification. They can also make entries up to $250,000, which eliminates the need to carry large sums of cash at the event and increases security measures. “Poker players competing at WSOP events typically face many roadblocks funding their entry at the casino and managing any payout,” said Seni Thomas, CEO and Founder of EDGE Markets. “In the past, players had to bring multiple checks from different accounts which complicated the deposit process and led to security issues of players walking around with large cash rewards. EDGE Boost simplifies this entire process and makes it entirely digital. Now these players can focus on their game without worrying about these extra factors. This partnership lays the groundwork for the future of gaming.” This focus complements player safety and strengthens WSOP’s appeal as an attractive event for poker players globally. “EDGE Boost is going to completely transform the WSOP experience,” said Greg Chochon, Chief Operating Officer at WSOP. “This partnership immediately enhances our brand and player experience through tangible benefits that make them feel safe and supported. Together, we are setting a new standard for how the rest of the gambling industry should operate. We also hope this improvement attracts more players to our events because of the frictionless financial process made possible by EDGE Boost, leading to a safer and easier-to-use system for all involved.” "EDGE Boost gives players what we've needed for years - seamless access to our money, without hassle or judgment," said Lexy Gavin-Mather, Professional Poker Player and Coach. EDGE Boost is also sponsoring an exclusive lounge at the WSOP in Las Vegas through July 11. It offers EDGE Boost cardholders a private space with refreshments, Wi-Fi, and autograph sessions from poker champions like 17-time WSOP Bracelet Winner Phil Hellmuth and WSOP Main Event Champion Jamie Gold. “EDGE Boost is more than a card; it’s a tech revolution for gaming,” Hellmuth said. “Instant access, ironclad security, and flawless control - all designed to let you play your game.” "If you're still traveling with cash, wiring money, or dealing with silly limits you're way behind,” Gold said. “EDGE Boost is a literal game changer! It's a Visa debit card built for serious players who want control over their bankrolls. It saves me so much time and keeps me safe! No brainer to sign up ASAP." About EDGE Boost EDGE Boost is the responsible financial platform for smart bettors. One of the first deposit accounts built exclusively for betting-related use, held with Cross River Bank, Member FDIC, and eligible for FDIC insurance up to $250,000 per depositor. As a neutral, third party, EDGE Boost provides financial segmentation and a holistic view to bettors for all their financial betting data, with custom tools, like personalized spending limitations and cashback incentives, available to help all bettors be more responsible. Customers experience frictionless, instant free betting that is compatible with almost any online or physical betting platform. *Deposit Checking accounts are held with Cross River Bank, Member FDIC. The EDGE Boost Visa Debit Card is a Visa® debit card issued by Cross River Bank, Member FDIC, pursuant to a license from Visa U.S.A. Inc. The EDGE Boost Visa Debit Card is not available to all residents of U.S. territories. For further information, please see our Terms of Service and Cardholder Agreement. If you think you or someone you know may have a gambling problem, call 1-800-GAMBLER. Contact Details Sterling Randle srandle@hotpaperlantern.com Company Website https://www.edgeboost.bet/

June 26, 2025 09:01 AM Eastern Daylight Time

This $13M Biotech Has $40M in Pentagon Funding – Here’s Why BiomX Could Be Biotech’s Best-Kept Secret

VentureBlock

With 3X Its Market Cap in Military Grants and Analyst Targets of $15-16, This Military-Backed Phage Therapy Pioneer Trades at Just $0.48 (NYSE: PHGE)*, all while their competitor (NYSE: ARMP) trades at over 6X ‎‎ BiomX Inc. (NYSE: PHGE)* presents an unusual situation in biotech: a company trading at just below a $13 million market cap that has secured $40 million in non-dilutive funding from the U.S. Defense Health Agency. This Pentagon backing, administered through the Naval Medical Research Command, has enabled the company to advance its bacteriophage therapies without the typical shareholder dilution that plagues early-stage biotechs. The military’s interest centers on antibiotic-resistant infections emerging from conflict zones. According to BiomX CEO Jonathan Solomon, medical personnel are “seeing soldiers coming out of the Ukraine war with extremely antibiotic-resistant infections.” This real-world crisis has elevated phage therapy, using viruses that naturally kill bacteria, from scientific curiosity to strategic priority. ‎ The Numbers Behind the Story BiomX’s recent Phase 2 DANCE trial results help explain the military’s confidence. The study of 41 patients with diabetic foot osteomyelitis showed: Statistically significant reduction in ulcer size by week 12 (p=0.046) Greater than 40% difference in healing between treatment and placebo groups by week 10 Significant improvement in ulcer depth at week 13 (p=0.048) Significant reduction in ulcer area expansion (p=0.017) No serious adverse events These results matter because diabetic foot infections lead to approximately 160,000 amputations annually in the U.S., creating an $8 billion healthcare burden. The same Staphylococcus aureus bacteria causing these civilian amputations also complicates combat wound care, making BX211 a dual-use technology. ‎ Beyond Military Applications While defense funding validates the technology, BiomX’s commercial opportunity spans multiple indications. The company’s BX004 program for cystic fibrosis demonstrated that 14.3% of patients (3 out of 21) completely cleared chronic Pseudomonas aeruginosa lung infections after 10 days of treatment, compared to 0% in the placebo group. One patient had carried the infection for 35 years before achieving clearance. BiomX estimates addressable markets of $2.5 billion globally for diabetic foot infections and $1.6 billion for cystic fibrosis. The FDA has already granted Fast Track and Orphan Drug designations to BX004, potentially accelerating the regulatory pathway. ‎ The Market Disconnect & Opportunity Current analyst coverage reveals a striking valuation gap. H.C. Wainwright maintains a Buy rating with a $15 price target, while Laidlaw & Company also rates the stock Buy with a $16 target. From recent trading levels around $0.52, these targets represent potential upside of approximately 2,800-2,900%. Laidlaw analyst Yale Jen called the BX211 Phase 2 results “an absolutely positive surprise,” characterizing the asset as “high value and clinically de-risked.” H.C. Wainwright’s assessment emphasizes the program’s advancement toward “important regulatory discussions” with the FDA. The disconnect becomes even more apparent when compared to peers. Armata Pharmaceuticals (NYSE: ARMP), the only other publicly-traded pure-play phage therapy company, trades at approximately $70 million, more than 5X BiomX’s valuation despite having just one clinical program compared to BiomX’s two Phase 2 assets and $40 million in military backing. ‎ Understanding the Opportunity Several factors contribute to BiomX's current valuation disconnect: Non-dilutive funding advantage: The $40 million military grant has funded clinical development without issuing new shares, preserving value for existing shareholders. Limited competition: No new drugs have been approved specifically for diabetic foot osteomyelitis in over 20 years, giving BiomX potential first-mover advantage in a massive unmet need. Impressive platform validation: Success in two separate indications (DFO and cystic fibrosis) demonstrates the broader applicability of the phage platform. Near-term catalysts: Phase 2b results for BX004 expected in Q1 2026, FDA meetings for BX211 Phase 2/3 design, and potential additional military funding or partnerships. ‎ The Broader Context BiomX operates within converging megatrends. The Biden administration has proposed $88.2 billion for biodefense over five years, while organizations like DARPA and ARPA-H are investing hundreds of millions in next-generation antimicrobials. NATO has formed a task force specifically to reintroduce phage therapy in military medicine. The company’s ability to address both military and civilian needs positions it uniquely as governments worldwide recognize antimicrobial resistance as a national security threat. With China producing 80-90% of antibiotic raw materials, supply chain vulnerabilities add urgency to developing alternative therapies. ‎ Looking Ahead BiomX’s story combines validated science, government backing, and massive market opportunities with a market cap that appears disconnected from fundamental value. The $40 million in Pentagon funding alone exceeds the company’s current market valuation by 3X, while clinical success and analyst targets suggest significant upside potential. As the company advances toward Phase 2/3 trials for BX211 and awaits Phase 2b results for BX004, the convergence of military necessity and civilian healthcare needs could transform this overlooked biotech into a key player in humanity’s fight against antibiotic-resistant infections. ‎ This article was syndicated from VentureBlock. ‎ ‎ Recent News Highlights BiomX: BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) ‎ ‎ * ⚠︎ Paid Advertisement Disclaimer: This content is a paid advertisement. Wall Street Wire has received compensation from BiomX Inc. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. We are not responsible for any price targets that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details ‎ media.globalmarkets@gmail.com

June 26, 2025 08:31 AM Eastern Daylight Time

Image

1 2 3 4 5 ... 3894